1-5 of 5
Naoki Furuya
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers

Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Yohei Matsui, Soichi Hirai, Ryota Nakamura, Kenji Morimoto, Naoki Furuya, Sachiko Arai, Yasuhiro Goto, Yoshihiko Sakata, Kazumi Nishino, Michiko Tsuchiya, Akihiro Tamiya, Go Saito, Satoshi Muto, Takayuki Takeda, Koji Date, Yasuhito Fujisaka, Satoshi Watanabe, Daichi Fujimoto, Hisanori Uehara, Mano Horinaka, Toshiyuki Sakai, Seiji Yano, Shinsaku Tokuda, Koichi Takayama
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF15.
https://doi.org/10.1158/1078-0432.CCR-24-1762
Published: 27 November 2024
View article titled, YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
Open the PDF for YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

Shinji Nakamichi, Kaoru Kubota, Toshihiro Misumi, Tetsuro Kondo, Shuji Murakami, Yoshimasa Shiraishi, Hisao Imai, Daijiro Harada, Kazutoshi Isobe, Hidetoshi Itani, Saori Takata, Hiroshi Wakui, Yuki Misumi, Satoshi Ikeda, Tetsuhiko Asao, Naoki Furuya, Shinobu Hosokawa, Yumiko Kobayashi, Yuichi Takiguchi, Hiroaki Okamoto
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (6): 1104–1110.
https://doi.org/10.1158/1078-0432.CCR-23-2568
Published: 15 March 2024
View article titled, Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
Open the PDF for Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study) in another window
Includes: Supplementary data
Journal Articles

A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630

Yuri Taniguchi, Tsuneo Shimokawa, Yuichi Takiguchi, Toshihiro Misumi, Yukiko Nakamura, Yosuke Kawashima, Naoki Furuya, Yoshimasa Shiraishi, Toshiyuki Harada, Hisashi Tanaka, Satoru Miura, Ayumi Uchiyama, Yoshiro Nakahara, Takaaki Tokito, Katsuhiko Naoki, Akihiro Bessho, Yasuhiro Goto, Masahiro Seike, Hiroaki Okamoto
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (20): 4402–4409.
https://doi.org/10.1158/1078-0432.CCR-22-1687
Published: 14 October 2022
View article titled, A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
Open the PDF for A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630 in another window
Includes: Supplementary data
Journal Articles

Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)

Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori, Satoru Miura, Hidetoshi Hayashi, Akito Hata, Yukihiro Toi, Yoshimasa Shiraishi, Nobuaki Mamesaya, Yuki Sato, Naoki Furuya, Jun Oyanagi, Yasuhiro Koh, Toshihiro Misumi, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3207–3213.
https://doi.org/10.1158/1078-0432.CCR-22-0602
Published: 02 August 2022
View article titled, Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)
Open the PDF for Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L) in another window
Includes: Supplementary data
Journal Articles

Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression

Azusa Tanimoto, Shingo Matsumoto, Shinji Takeuchi, Sachiko Arai, Koji Fukuda, Akihiro Nishiyama, Kiyotaka Yoh, Takaya Ikeda, Naoki Furuya, Kazumi Nishino, Yuichiro Ohe, Koichi Goto, Seiji Yano
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (5): 1410–1420.
https://doi.org/10.1158/1078-0432.CCR-20-2853
Published: 01 March 2021
View article titled, Proteasome Inhibition Overcomes ALK-TKI Resistance in <em>ALK</em>-Rearranged/<em>TP53</em>-Mutant NSCLC via Noxa Expression
Open the PDF for Proteasome Inhibition Overcomes ALK-TKI Resistance in <em>ALK</em>-Rearranged/<em>TP53</em>-Mutant NSCLC via Noxa Expression in another window
Includes: Supplementary data